Interleukin 1α and interleukin 18 in patients with vitiligo – Results of a case-control study - 26/02/23
, Daria Przybylska b , Andrzej Borzęcki aAbstract |
Introduction |
Vitiligo is a depigmenting disorder resulting from loss of functional melanocytes in the skin. Variety of inflammatory mediators participate in the regulation of melanogenesis in melanocytes: interleukin-18 (IL-18), interleukin-33, granulocyte-macrophage colony stimulating factor, interferon-γ, prostaglandin E2 have the effect of promoting melanogenesis, while interleukin-1 (IL-1), interleukin-4, interleukin-6, interleukin-17 and tumor necrosis factor can inhibit melanogenesis.
Aim |
Evaluation of IL-1α and IL-18 levels in peripheral blood in patients with vitiligo compared to healthy controls.
Materials and methods |
Fifty patients aged 18–81 with vitiligo participated in the study. The control group consisted of 38 healthy people. Venous blood samples were obtained from each participant. Serum IL-1α and IL-18 concentrations were determined using the enzyme-linked immunoabsorbent assay (ELISA).
Results |
Among patients with vitiligo, the mean concentration of IL-1α was 0.13 (± 0.535) pg/mL, while in the control group it was 0.51 (± 1.51). There were no statistically significant differences in IL-1α concentrations between patients in the study group compared to the control group (p > 0.05). In the study group, the mean IL-18 concentration was 141.05 (± 136.33) pg/mL vs 137.33 (± 105.83) pg/mL in the controls. There were no statistically significant differences in IL-18 concentrations between patients in the study group compared to the controls (p > 0.05). In the Spearman correlation test, no correlation was confirmed between IL1α and IL-18 concentrations in the group of patients with vitiligo vs healthy people.
Conclusions |
There is no correlation between Il-1 and Il-18 concentration in the blood sera of patients with vitiligo.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | IL-1α is a melanogenesis inhibitor. |
• | No significant difference in IL-1α concentration between healthy subjects and vitiligo patients |
• | IL-18 is melanogenesis promotor. |
• | No significant difference in IL-18 concentrationbetween healthy subjects and patients with vitiligo. |
• | There is no correlation between IL-1α and IL-18 in patients with vitiligo. |
Keywords : Interleukin 1α, Interleukin 18, Vitiligo
Plan
Vol 160
Article 114364- avril 2023 Retour au numéro
Article précédent
- SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy
- Dominique Croteau, Tomas Baka, Sara Young, Huamei He, Jordan M. Chambers, Fuzhong Qin, Marcello Panagia, David R. Pimentel, James A. Balschi, Wilson S. Colucci, Ivan Luptak
- Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases
- Fuyuki F. Inagaki, Hiroaki Wakiyama, Aki Furusawa, Ryuhei Okada, Takuya Kato, Daiki Fujimura, Shuhei Okuyama, Hiroshi Fukushima, Seiichiro Takao, Peter L. Choyke, Hisataka Kobayashi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?